IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.
The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback